Skip to main content
Figure 1 | Molecular Neurodegeneration

Figure 1

From: The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Figure 1

Everolimus penetrates the blood-brain barrier in R6/2 HD transgenic mice. Plasma (A) and brain (B) everolimus concentrations were measured 4 and 24 hours after the last dose following two weeks of treatment (black-bar = 10 μmol/kg, cross-hatched bar = 30 μmol/kg). Brain/plasma ratios (calculated as the ratio of brain to plasma concentration × 100) are higher than the reported [29] level of blood contamination (~6%) at 24, but not at 4 hours (C). Shown are mean ± SE. n = 3.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326